Merck & Co., Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted
Merck & Co., Inc. (MRK) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of $1.63 per share for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2018-02-27
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2015-09-30 was $0.65, a 170.83% increase year-over-year.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2015-06-30 was $0.27, a 55.74% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2015-03-31 was $0.36, a 21.74% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2014-09-30 was $0.24.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2015 was $1.63, a 56.18% decline from fiscal 2014.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2014 was $3.72.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2009 was $1.90, a 106.52% increase from fiscal 2008.
- Merck & Co., Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2008 was $0.92.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month as first filed | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|
| 2015-12-31 | $1.63 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $0.65 10-Q · filed 2016-11-07 | $1.28 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | $0.27 10-Q · filed 2016-08-08 | $0.63 10-Q · filed 2016-08-08 | |||
| 2015-03-31 | $0.36 10-Q · filed 2016-05-09 | $0.35 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $3.72 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $0.24 10-Q · filed 2015-11-05 | $1.29 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $0.61 10-Q · filed 2015-08-06 | $1.04 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $0.46 10-Q · filed 2015-05-07 | ||||
| 2009-12-31 | $1.90 10-K · filed 2012-02-28 | ||||
| 2008-12-31 | $0.92 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |